Table of Contents
Key Points
- Kenneth Frazier’s Merck investment lost $8.91M in 23 days, reflecting a broader decline in Merck’s stock performance.
- Merck shares fell 9.89%, dropping below $300 billion in market cap, impacting Frazier’s stake valued at $81.2 million.
- Merck’s year-to-date gains for 2024 slip to 5.61% amid broader market fluctuations.
Kenneth Frazier, the trailblazing Black executive and former chairman of Merck & Co., has experienced a notable decrease in the market value of his investment in the pharmaceutical company. This decline reflects a broader downturn in Merck’s stock performance.
Recent market data tracked by Billionaires.Africa highlights a significant $8.91 million drop in Frazier’s stake over the past 23 days. Previously, his stake had already fallen by $4.72 million between June 24 and July 20, reducing from $93.7 million to $89.05 million.
Merck shares slump 9.89%, market cap drops below $300 billion
Merck & Co. maintains its position as a leading pharmaceutical company, boasting a diverse portfolio of prescription drugs, vaccines, biological therapies, animal health products, and consumer healthcare solutions. Frazier, a top Black executive, holds a 0.028 percent stake in Merck & Co., comprising 705,220 shares valued at over $80.2 million.
Merck’s shares have experienced a decline of nearly 10 percent on the NYSE over the past 23 days, dropping from $127.78 on July 29 to $115.14. This decline has pushed the company’s market capitalization below $300 billion, affecting investors, including Frazier.
The recent decline in Merck’s shares has resulted in an $8.91 million decrease in the market value of Frazier’s stake, from $90.11 million on July 29 to $81.2 million. Despite this decline, he remains one of the wealthiest Black executives in the U.S.
Your Money and Your life
Merck & Co. has provided modest returns for investors this year, with its NYSE-listed shares increasing 5.61 percent year-to-date. An investment of $100,000 in Merck at the beginning of 2024 would now be valued at $105,610, reflecting a gain of $5,610.
The intelligence satisfies curiosity. The paid briefings satisfy strategy.
Every Monday, Elite subscribers receive an Investor Memo breaking down the deal, the structure and the positioning behind the week's most consequential African wealth story - the kind of analysis that doesn't appear anywhere else.
Twice a month, a Wealth Intelligence brief profiles a single billionaire's holdings, cash flows and expansion pipeline in detail no public source matches.
→ Executive ($25/mo): Daily newsletter + Deep-Dive Reports
→ Elite ($75/mo): Everything above + Investor Memos + Wealth Intelligence + Quarterly Analyst Briefings
Subscribe now
